A Conversation With Revolution Medicines' Chief Development Officer
- In Chicago for the American Society of Clinical Oncology Annual Meeting, SurvivorNet sat down with Dr. Alan Sandler to discuss the excitement surrounding a potential new therapy for pancreatic cancer. It’s part of a new class of drugs that target the mutation behind 30% of all cancers, RAS mutations, which may be opening new possibilities for people facing some of the toughest diagnoses.
- RAS mutations are found in roughly 30% of all cancers, including pancreatic, colorectal, and lung cancers. Researchers say recent breakthroughs are transforming RAS from a target once considered “undruggable” into one of the most promising areas in cancer research.
- Dr. Sandler describes the progress as a “watershed moment,” saying the success may open the door to new therapies for a broad range of RAS-driven cancers.
At the world’s largest cancer conference (ASCO’s Annual Meeting), we asked the Chief Development Officer of Revolution Medicines, the biotech company behind the breakthrough investigational therapy daraxonrasib, what this latest progress could mean for pancreatic cancer patients.
Read MoreRevolution Medicines has become one of the most closely watched companies in pancreatic cancer after reporting encouraging results with daraxonrasib, which is an investigational therapy designed to target these cancers driven by RAS mutations.
Supporting Pancreatic Cancer Patients
- A New Drug Just Changed The Conversation Around Pancreatic Cancer — And Experts Say This Is Only The Beginning
- 'Crying in H Mart,' Musician Michelle Zauner's Candid Memoir Detailing Her Mother's Battle With Pancreatic Cancer, Celebrates One Year Since its Publication
- Big News for PARP Inhibitors: They Can Work in Pancreatic Cancer, Too
In a disease where treatment advances have been frustratingly rare, the drug demonstrated meaningful anti-tumor activity in patients with previously treated pancreatic cancer, fueling optimism that new therapies may finally begin to change outcomes for some patients facing one of the deadliest cancer diagnoses.
“It’s a watershed moment,” Dr. Sandler says. “You’re seeing this dramatic impact, and I think it’s literally opened the floodgates for what can be done with RAS.”
For patients and families, the implications stretch beyond pancreatic cancer. The promise of daraxonrasib has renewed hope that other RAS-driven cancers — long considered among the most challenging to target — may also one day be treated with similarly effective therapies.
Learn more about SurvivorNet's rigorous medical review process.
